Loading...
XHKG
8158
Market cap21mUSD
Dec 04, Last price  
0.56HKD
1D
-1.75%
1Q
-29.11%
Jan 2017
-98.90%
IPO
-95.33%
Name

China Regenerative Medicine International Ltd

Chart & Performance

D1W1MN
XHKG:8158 chart
P/E
9.60
P/S
1.88
EPS
0.06
Div Yield, %
—
Shrs. gr., 5y
28.18%
Rev. gr., 5y
13.57%
Revenues
91m
+30.41%
42,427,00064,952,00088,760,00024,448,00030,0002,621,000128,0001,377,000510,0002,817,00027,751,000356,987,000755,520,00072,952,00047,971,000185,339,000282,897,000231,612,00069,487,00090,617,000
Net income
18m
P
1,777,000-374,000-3,457,00021,092,000-64,569,000-42,061,000-57,109,000-61,320,000-263,442,000-250,098,000-190,902,000-184,502,000-237,738,000-1,193,501,000-447,743,000-289,708,00051,827,0004,555,000-107,699,00017,752,000
CFO
18m
+188.80%
4,710,000-1,523,000-8,472,000-18,847,000-9,444,000-102,726,00022,251,000-90,007,000-126,033,000-218,325,000-99,117,000-460,893,000-217,755,00018,751,000-23,332,000-397,741,000-3,022,000-17,654,0006,338,00018,304,000
Dividend
Sep 24, 20020 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
URL
http://www.crmi.hk/
IPO date
Jul 18, 2001
Employees
29
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑042016‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT